[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641635":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":24,"id":52,"slug":24,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":24,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":24,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":24,"overallStatus":71,"whyStopped":24,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of Missouri-Columbia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Insulin (Doppler)","EXPERIMENTAL","Human insulin (160 IU) will be administered using an intra-nasal device",[13],"Drug: human insulin",{"label":15,"type":10,"description":16,"interventionNames":17},"Insulin (MRI)","Human insulin (160 IU) will be administered using an intra-nasal device.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","human insulin","Participants will be administered human insulin (160 IU) using an intra-nasal device.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Jacqueline Limberg","CONTACT","573-882-2544","limberglab@missouri.edu",[32],{"facility":33,"status":24,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of Missouri","Columbia","Missouri","65211","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-92.33407,38.95171,{"lat":43,"lon":42},[46,47],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},{"name":27,"role":48,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Jacqueline K Limberg, PhD","Associate Professor","100641635",false,"NCT07653464","Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity","Inclusion Criteria:\n\n* 18 to 65 years of age\n\nIndividuals with obesity and comorbid IR\n\n* BMI 30-45 kg\u002Fm2\n* Waist circumference ≥102 cm (men) or ≥88 cm (women)\n* HOMA-IR ≥2.5\n\nHealthy normal weight adults\n\n* BMI 18-25 kg\u002Fm2\n* Waist circumference \\\u003C94 cm (men) and \\\u003C80 cm (women)\n* HOMA-IR \\\u003C2\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding\n* Unable to provide consent\n* Diabetes or polycystic ovarian syndrome\n* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke\n* Nerve\u002Fneurologic disease\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg and\u002For diastolic blood pressure \\>100 mmHg)\n* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)\n* Current smoking, tobacco, nicotine use\n* Use of pharmacological therapy for weight loss\n* Body weight change \\>10% within the last 6 months\n* Adherence to \\>150 min\u002Fweek of moderate-to-vigorous physical activity\u002Fexercise\n* Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months\n* Claustrophobia\n* Non-MRI compatible metal implants",true,"ALL","18 Years","65 Years",{"count":62,"type":63},64,"ESTIMATED","INTERVENTIONAL",[66],"EARLY_PHASE1","In the present study, we seek to determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.",[69,70],"Obesity (BMI>30)","Insulin Resistance","NOT_YET_RECRUITING","2026-06-12",{"date":74,"type":75},"2026-06-17","ACTUAL",{"date":77,"type":63},"2026-08",{"date":79,"type":63},"2032-06",{"name":5,"class":6},1]